Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Research output: Contribution to journalArticle

Abstract

In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased hypoglycemia with glimepiride was driven by the 6 mg/day dose; it was therefore of interest to assess whether the risk of hypoglycemia is also different between vildagliptin and a low (2 mg/day) dose of glimepiride.

Details

Authors
  • Bo Ahrén
  • James Edward Foley
  • Sylvie Dejager
  • Mouna Akacha
  • Qing Shao
  • Guenter Heimann
  • Markus Dworak
  • Anja Schweizer
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
Original languageEnglish
JournalDiabetes therapy : research, treatment and education of diabetes and related disorders
Early online date2014 Sep 18
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available